Biotech News

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

Intellia (NTLA)ir.intelliatx.com2026-06-01 19:39 ESTClinical readout

CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that data from the global Phase 3 HAELO clinical trial

Open original release

Related news

No closely related headlines were available from the latest feed snapshot.

View all latest news

Intellia

Intellia Therapeutics is a gene-editing company focused on in vivo CRISPR-based medicines. Investors watch how the platform translates into durable clinical proof, delivery confidence, and a broader pipeline.

Recent company news

NTLAIntellia2026-06-13 07:31:35 EST

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

NTLAIntellia2026-05-11 15:37:08 EST

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

NTLAIntellia2026-05-06 18:46:00 EST

Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026

NTLAIntellia2026-05-05 15:34:14 EST

Intellia Therapeutics to Participate in Upcoming Investor Conferences

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States